4.8 Article

Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas

Journal

SCIENCE
Volume 330, Issue 6009, Pages 1410-1413

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1194472

Keywords

-

Funding

  1. National Cancer Institute [R01 CA125970]
  2. Barnes-Jewish Hospital Foundation
  3. Kling Family Foundation
  4. Tumori Foundation
  5. Horncrest Foundation
  6. Research to Prevent Blindness, Inc.
  7. NIH [P30 EY02687c]
  8. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR007279-31A1]
  9. Washington University

Ask authors/readers for more resources

Metastasis is a defining feature of malignant tumors and is the most common cause of cancer-related death, yet the genetics of metastasis are poorly understood. We used exome capture coupled with massively parallel sequencing to search for metastasis-related mutations in highly metastatic uveal melanomas of the eye. Inactivating somatic mutations were identified in the gene encoding BRCA1-associated protein 1 (BAP1) on chromosome 3p21.1 in 26 of 31 (84%) metastasizing tumors, including 15 mutations causing premature protein termination and 5 affecting its ubiquitin carboxyl terminal hydrolase domain. One tumor harbored a frameshift mutation that was germline in origin, thus representing a susceptibility allele. These findings implicate loss of BAP1 in uveal melanoma metastasis and suggest that the BAP1 pathway may be a valuable therapeutic target.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available